Endo Financials Strong, But Shareholder Calls For Sale Of Company
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO stepping down and no R&D leader on board, as officials evaluate pipeline.
You may also be interested in...
Endo Explains HealthTronics Acquisition to Wall Street: Relationships With Urologists Are Key
Endo's pending acquisition of HealthTronics and its settlement with Impax and Sandoz over generic Opana ER removes some near-term pressure on its shares.
Endo Explains HealthTronics Acquisition to Wall Street: Relationships With Urologists Are Key
Endo's pending acquisition of HealthTronics and its settlement with Impax and Sandoz over generic Opana ER removes some near-term pressure on its shares.
Endo Branches Out With $370M Indevus Acquisition
Re-submission of Nebido NDA in the wings, sales force will target general practitioners with urology, endocrinology drugs to general practitioners.